Isobe Yoshiaki, Tobe Masanori, Ogita Haruhisa, Kurimoto Ayumu, Ogino Tetsuhiro, Kawakami Hajime, Takaku Haruo, Sajiki Hironao, Hirota Kosaku, Hayashi Hideya
Research Division, Discovery Research Laboratories II, Sumitomo Pharmaceuticals Co. Ltd., Konohana-ku, 554-0022, Osaka, Japan.
Bioorg Med Chem. 2003 Aug 15;11(17):3641-7. doi: 10.1016/s0968-0896(03)00369-9.
Recently we reported the adenine derivatives (2-4) as new interferon (IFN) inducers. In the present study, we conducted a detailed structure and activity relationship study of 4 and its related derivatives on IFN inducing activity. From this study, we found that compound 4 exhibited the most potent IFN inducing activity in vitro with a minimum effective concentration of 0.01 microM, and 4 also showed strong IFN-inducing activity at doses of more than 0.3mg/kg by oral administration in mice. This potency was 10-fold stronger than that of Imiquimod. Moreover, 4 did not cause emesis in ferrets even at doses as high as 10mg/kg, whereas, 80% of animals were emetic when orally administered with the same dose of Imiquimod. These results indicate that compound 4 is superior to Imiquimod with respect to efficacy and safety.
最近我们报道了腺嘌呤衍生物(2 - 4)作为新型干扰素(IFN)诱导剂。在本研究中,我们对化合物4及其相关衍生物的干扰素诱导活性进行了详细的构效关系研究。通过该研究,我们发现化合物4在体外表现出最有效的干扰素诱导活性,最低有效浓度为0.01微摩尔,并且化合物4通过小鼠口服给药剂量超过0.3毫克/千克时也显示出较强的干扰素诱导活性。这种效力比咪喹莫特强10倍。此外,化合物4即使在高达10毫克/千克的剂量下也不会引起雪貂呕吐,而相同剂量的咪喹莫特口服给药时80%的动物会呕吐。这些结果表明化合物4在疗效和安全性方面优于咪喹莫特。